Drug · CHEMBL862
GUANFACINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GUANFACINE. Drugs and targets, record CHEMBL862. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL862
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 26 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/150 |
| ADRA2B | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/151 |
| ADRA2C | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/152 |
Source ChEMBL
Diseases26
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Approval | EMA Human Drugs and TTD | 20 | 17 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| smoking behavior | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=EFO_0004318 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| delirium | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0045057 |
| nicotine dependence | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0008575 |
| Alzheimer disease | Phase 3 | ClinicalTrials.gov and TTD | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004975 |
| hypertensive disorder | Approval | ATC | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| Abnormal emotional state | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0100851 |
| Borderline personality disorder | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012076 |
| Cognitive impairment | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0100543 |
1 to 10 of 26Source Open Targets
See all 26 diseasesTrials66
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00734578 | Efficacy and Safety of SPD503 in Combination With Psychostimulants | Phase 3 | 461 | 2010-11-23 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00997984 | Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) | Phase 3 | 340 | 2011-10-26 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00150618 | Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 | Phase 3 | 324 | 2009-10-15 | guanfacine | Its name | ClinicalTrials.gov |
| NCT01081132 | Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl | Phase 3 | 314 | 2014-05-23 | guanfacine | Its name | ClinicalTrials.gov |
| NCT01133847 | Interventions for Children With Attention and Reading Disorders | Phase 4 | 222 | 2017-04-11 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00429273 | Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder | Phase 4 | 212 | 2017-06-14 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00935493 | Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects | 154 | 2014-08-11 | guanfacine | Its name | ClinicalTrials.gov | |
| NCT02051309 | Guanfacine Clinical Trial for Smoking Cessation | Phase 2 | 121 | 2021-12-29 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00613015 | Stress and Medication Effects on Cocaine Cue Reactivity | Phase 2 | 109 | 2013-11-08 | guanfacine | Its name | ClinicalTrials.gov |
| NCT00773357 | Modeling Stress-precipitated Smoking Behavior for Medication Development | Phase 2 | 100 | 2022-08-01 | guanfacine | Its name | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsComparisons in its trials36
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SPD503 vs PLACEBO: serious adverse events | 4 of 157 | 2 of 155 | 312 | NCT01081132 | Trial comparisons |
| Guanfacine 6mg/Day ER vs Placebo: deaths from any cause | 0 of 58 | 0 of 63 | 121 | NCT02051309 | Trial comparisons |
| Guanfacine 6mg/Day ER vs Placebo: serious adverse events | 0 of 58 | 0 of 63 | 121 | NCT02051309 | Trial comparisons |
| Guanfacine vs Placebo: deaths from any cause | 0 of 50 | 0 of 50 | 100 | NCT00773357 | Trial comparisons |
| Guanfacine vs Placebo: serious adverse events | 0 of 50 | 0 of 50 | 100 | NCT00773357 | Trial comparisons |
| Guanfacine vs Placebo: deaths from any cause | 9 of 50 | 10 of 50 | 100 | NCT04578886 | Trial comparisons |
| Guanfacine vs Placebo: serious adverse events | 0 of 50 | 0 of 50 | 100 | NCT04578886 | Trial comparisons |
| Stimulant and GXR vs Stimulant and PLB: serious adverse events | 0 of 47 | 0 of 48 | 95 | NCT01985581 | Trial comparisons |
| Guanfacine vs Placebo: deaths from any cause | 0 of 40 | 0 of 44 | 84 | NCT02882854 | Trial comparisons |
| Guanfacine vs Placebo: serious adverse events | 0 of 40 | 0 of 44 | 84 | NCT02882854 | Trial comparisons |
1 to 10 of 36
See all 36 comparisons in its trialsPapers from its trials49
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials20
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 4 | 3 | ConductCognition |
| Continuous Performance Test | 2 | 0 | ConductCognition |
| Digit Span Test | 2 | 0 | ConductCognition |
| Stroop Color-Word Test | 2 | 1 | ConductCognition |
| AX Continuous Performance Test | 1 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 1 | 0 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| Go/No-Go Task | 1 | 1 | ConductCognition |
| Letter-Number Sequencing Task | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 1 | ConductCognition |
1 to 10 of 20
See all 20 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL862
GET https://conductscience.org/api/drugs/v1/CHEMBL862/diseases?page=2